Zygmont Chester Stanley III reported grant involving 208,073 shares of REVELATION BIOSCIENCES, INC. at $0.00 for $0 on Aug 17, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Chief Financial Officer
Chief Financial Officer
Filed Aug 18, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$0Shares × reported price
Shares traded
208,073Common Stock
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
208,073Direct
Trade date
Aug 17, 2026Grant
Filed
Aug 18, 2026, 5:00 PM ET1-day reporting delay
Accession
0001193125-26-355661Code A · Transaction 2950
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Aug 17, 2026Gift208,073$0.00$0Trade 2952
Aug 17, 2026Gift208,073$0.00$0Trade 2951
3 transaction rows in this filing. Joint filers share the same rows.

REVB price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
REVB · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +6.3%1w ago +0.9%1d ago −6.3%
Returns since7d −1.8%30d −17%90d180d1y

Footnotes in full

F1: These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary of the grant date, provided that the Reporting Person remains continuously employed by or provides services to the Company or any subsidiary through the applicable vesting date; and provided, further that such vesting could be accelerated upon the achievement of certain performance milestones. F2: Shares are held by The Zygmont Family Trust Dated October 25, 2016, with respect to which Chester S Zygmont III is a trustee. F3: Shares are held by Czeslaw Capital Fund, LLC. Chester S Zygmont III is the sole manager of Czeslaw Capital Fund, LLC.